ATE348878T1 - Sich in schlagende kardiomyozyten verwandelnde stammzellen - Google Patents

Sich in schlagende kardiomyozyten verwandelnde stammzellen

Info

Publication number
ATE348878T1
ATE348878T1 AT02773854T AT02773854T ATE348878T1 AT E348878 T1 ATE348878 T1 AT E348878T1 AT 02773854 T AT02773854 T AT 02773854T AT 02773854 T AT02773854 T AT 02773854T AT E348878 T1 ATE348878 T1 AT E348878T1
Authority
AT
Austria
Prior art keywords
stem cells
cardiomyocytes
cells
beating cardiomyocytes
spoc cells
Prior art date
Application number
AT02773854T
Other languages
English (en)
Inventor
Neal D Epstein
Thiru V Gopal
Steve O Winitsky
Shahin Hassanzadeh
Original Assignee
Us Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Health filed Critical Us Health
Application granted granted Critical
Publication of ATE348878T1 publication Critical patent/ATE348878T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5073—Stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/34—Muscles; Smooth muscle cells; Heart; Cardiac stem cells; Myoblasts; Myocytes; Cardiomyocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0657—Cardiomyocytes; Heart cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C12N2500/20—Transition metals
    • C12N2500/24—Iron; Fe chelators; Transferrin
    • C12N2500/25—Insulin-transferrin; Insulin-transferrin-selenium
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/11—Epidermal growth factor [EGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2503/00—Use of cells in diagnostics
    • C12N2503/02—Drug screening

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Cardiology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Vascular Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
AT02773854T 2001-10-22 2002-10-22 Sich in schlagende kardiomyozyten verwandelnde stammzellen ATE348878T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/003,400 US20030082153A1 (en) 2001-10-22 2001-10-22 Stem cells that transform to beating cardiomyocytes

Publications (1)

Publication Number Publication Date
ATE348878T1 true ATE348878T1 (de) 2007-01-15

Family

ID=21705682

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02773854T ATE348878T1 (de) 2001-10-22 2002-10-22 Sich in schlagende kardiomyozyten verwandelnde stammzellen

Country Status (8)

Country Link
US (3) US20030082153A1 (de)
EP (1) EP1444329B1 (de)
JP (1) JP4377690B2 (de)
AT (1) ATE348878T1 (de)
AU (1) AU2002337949B1 (de)
CA (1) CA2464088A1 (de)
DE (1) DE60216959D1 (de)
WO (1) WO2003035838A2 (de)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE42643E1 (en) 1991-03-27 2011-08-23 Panasonic Corporation Communication system
USRE39890E1 (en) 1991-03-27 2007-10-23 Matsushita Electric Industrial Co., Ltd. Communication system
USRE40241E1 (en) 1991-03-27 2008-04-15 Matsushita Electric Industrial Co., Ltd. Communication system
US6724976B2 (en) * 1992-03-26 2004-04-20 Matsushita Electric Industrial Co., Ltd. Communication system
CN1032099C (zh) * 1992-03-26 1996-06-19 松下电器产业株式会社 通信系统
USRE38513E1 (en) 1992-03-26 2004-05-11 Matsushita Electric Industrial Co., Ltd. Communication system
US6728467B2 (en) * 1992-03-26 2004-04-27 Matsushita Electric Industrial Co., Ltd. Communication system
US5802241A (en) 1992-03-26 1998-09-01 Matsushita Electric Industrial Co., Ltd. Communication system
US7158577B1 (en) 1992-03-26 2007-01-02 Matsushita Electric Industrial Co., Ltd. Communication system
US7894541B2 (en) * 1992-03-26 2011-02-22 Panasonic Corporation Communication system
US7166280B2 (en) * 2000-04-06 2007-01-23 Franco Wayne P Combination growth factor therapy and cell therapy for treatment of acute and chronic heart disease
US20100303769A1 (en) * 2000-04-06 2010-12-02 Franco Wayne P Combination growth factor therapy and cell therapy for treatment of acute and chronic heart disease
FR2819265B1 (fr) * 2001-01-10 2004-01-02 Centre Nat Rech Scient Cellules du tissu adipeux extramedullaire et leurs applications dans la reconstitution des lignees hematopoietiques
US7150990B2 (en) * 2002-03-06 2006-12-19 Reprocell, Inc. Self-renewing pluripotent hepatic stem cells
US8263375B2 (en) 2002-12-20 2012-09-11 Acea Biosciences Dynamic monitoring of activation of G-protein coupled receptor (GPCR) and receptor tyrosine kinase (RTK) in living cells using real-time microelectronic cell sensing technology
AU2003270051A1 (en) * 2002-08-29 2004-03-19 Baylor College Of Medicine Heart derived cells for cardiac repair
US9612234B2 (en) 2008-05-05 2017-04-04 Acea Biosciences, Inc. Data analysis of impedance-based cardiomyocyte-beating signals as detected on real-time cell analysis (RTCA) cardio instruments
US11346797B2 (en) 2002-12-20 2022-05-31 Agilent Technologies, Inc. System and method for monitoring cardiomyocyte beating, viability, morphology and electrophysiological properties
US10551371B2 (en) 2003-11-10 2020-02-04 Acea Biosciences, Inc. System and method for monitoring cardiomyocyte beating, viability and morphology and for screening for pharmacological agents which may induce cardiotoxicity or modulate cardiomyocyte function
US10539523B2 (en) 2002-12-20 2020-01-21 Acea Biosciences, Inc. System and method for monitoring cardiomyocyte beating, viability, morphology, and electrophysiological properties
US10215748B2 (en) 2002-12-20 2019-02-26 Acea Biosciences, Inc. Using impedance-based cell response profiling to identify putative inhibitors for oncogene addicted targets or pathways
ITRM20030376A1 (it) * 2003-07-31 2005-02-01 Univ Roma Procedimento per l'isolamento e l'espansione di cellule staminali cardiache da biopsia.
EP1692258A4 (de) 2003-11-12 2007-03-21 Xiao Xu Elektronische echtzeit-zellwahrnehmungssysteme und anwendungen für tests auf zellbasis
US8859273B2 (en) * 2003-12-24 2014-10-14 Medtronic, Inc. Methods of using HCN genes to treat cardiac arrhythmias
MXPA06008932A (es) * 2004-02-06 2007-01-26 Theradigm Inc Composiciones y metodos que se refieren al cultivo de las celulas madre neurales con celulas estromales de medula osea.
US20090074669A1 (en) 2004-03-31 2009-03-19 Ebert Steven N PNMT as a novel marker for progenitor cells
JP2007534946A (ja) * 2004-04-23 2007-11-29 アメリカ合衆国 幹細胞に特異的に結合するモノクローナル抗体の使用
US8318488B1 (en) 2004-05-11 2012-11-27 Axiogenesis Ag Assay for drug discovery based on in vitro differentiated cells
EP1781371A4 (de) * 2004-07-19 2007-12-19 Univ Columbia Assay-system zur überwachung der wirkungen von genetisch hergestellten zellen zur veränderung der funktion eines syncytiums
US7897397B2 (en) 2004-07-27 2011-03-01 Kowa Company, Ltd. Cell fusion promoter and utilization of the same
US11660317B2 (en) 2004-11-08 2023-05-30 The Johns Hopkins University Compositions comprising cardiosphere-derived cells for use in cell therapy
JP4783909B2 (ja) 2005-03-04 2011-09-28 国立大学法人京都大学 心臓組織由来の多能性幹細胞
US20080241111A1 (en) * 2005-03-04 2008-10-02 Kyoto University Pluripotent Stem Cell Derived from Cardiac Tissue
CN103356706B (zh) * 2005-03-31 2016-01-20 斯丹姆涅恩有限公司 促进无疤愈合或改善皮肤外观的美容制剂
US20080213231A1 (en) * 2005-07-15 2008-09-04 Kyoto University Pluripotent Stem Cell Cloned From Single Cell Derived From Skeletal Muscle Tissue
FR2896511B1 (fr) * 2006-01-26 2012-10-26 Centre Nat Rech Scient Procede de culture de cellules issues du tissu adipeux et leurs applications.
TW200734462A (en) 2006-03-08 2007-09-16 In Motion Invest Ltd Regulating stem cells
WO2008040027A2 (en) * 2006-09-28 2008-04-03 The Regents Of The University Of California Directed differentiation and maturation of stem cell-derived cardiomyocytes
WO2008043099A2 (en) 2006-10-06 2008-04-10 Medtronic, Inc. Hybrid pacing system
EP2087098A4 (de) * 2006-11-09 2010-03-31 Univ Johns Hopkins Entdifferenzierung der kardiomyozyten erwachsener säugetiere in herzstammzellen
US20100278787A1 (en) * 2007-07-18 2010-11-04 Cellartis Ab Cardiomyocyte-like cell clusters derived from hbs cells
WO2009036220A2 (en) 2007-09-12 2009-03-19 The Regents Of The University Of California Compositions and methods for improving the functional efficacy of stem cell-derived cardiomyocytes
WO2009092005A2 (en) * 2008-01-18 2009-07-23 The J. David Gladstone Institutes Methods of generating cardiomyocytes and cardiac progenitors and compositions
CA2717962C (en) * 2008-03-27 2019-05-14 Mount Sinai School Of Medicine Of New York University Human cardiovascular progenitor cells
WO2009137440A1 (en) 2008-05-05 2009-11-12 Acea Biosciences, Inc. Label-free monitoring of excitation-contraction coupling and excitable cells using impedance based systems with millisecond time resolution
RU2642282C1 (ru) * 2009-07-09 2018-01-24 Янссен Байотек, Инк. Клетки, производные от кардиальной ткани
US9249392B2 (en) 2010-04-30 2016-02-02 Cedars-Sinai Medical Center Methods and compositions for maintaining genomic stability in cultured stem cells
US9845457B2 (en) 2010-04-30 2017-12-19 Cedars-Sinai Medical Center Maintenance of genomic stability in cultured stem cells
WO2012098260A1 (en) 2011-01-21 2012-07-26 Axiogenesis Ag A non-viral system for the generation of induced pluripotent stem (ips) cells
CN103998938B (zh) * 2011-10-17 2016-06-15 霍夫曼-拉罗奇有限公司 风险患者和中风原因的基于肌钙蛋白和bnp的诊断
US9884076B2 (en) 2012-06-05 2018-02-06 Capricor, Inc. Optimized methods for generation of cardiac stem cells from cardiac tissue and their use in cardiac therapy
EP3563859B1 (de) 2012-08-13 2021-10-13 Cedars-Sinai Medical Center Von kardiosphären abgeleitete exosomen zur geweberegeneration
US20150337266A1 (en) * 2012-12-28 2015-11-26 Kyoto University Method for producing induced pluripotent stem cells, cardiomyocytes or precursor cells thereof
US10160954B2 (en) 2013-01-23 2018-12-25 The Regents Of The University Of California Engineered physical alignment of stem cell-derived cardiomyocytes
US9493742B2 (en) 2013-03-15 2016-11-15 Emory University Purification of cell mixtures using molecular beacons targeting cell specific RNA
US10087436B2 (en) 2014-02-06 2018-10-02 The Regents Of The University Of California Electrophysiologically mature cardiomyocytes and methods for making same
EP4494699A3 (de) 2014-10-03 2025-04-30 Cedars-Sinai Medical Center Kardiosphären-zellen und durch diese zellen sekretierte exosomen bei der behandlung von muskeldystrophie
US12066428B2 (en) 2015-11-20 2024-08-20 Agilent Technologies, Inc. Cell-substrate impedance monitoring of cancer cells
WO2017123662A1 (en) 2016-01-11 2017-07-20 Cedars-Sinai Medical Center Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of heart failure with preserved ejection fraction
WO2017210652A1 (en) 2016-06-03 2017-12-07 Cedars-Sinai Medical Center Cdc-derived exosomes for treatment of ventricular tachyarrythmias
US11541078B2 (en) 2016-09-20 2023-01-03 Cedars-Sinai Medical Center Cardiosphere-derived cells and their extracellular vesicles to retard or reverse aging and age-related disorders
EP3589299B1 (de) 2017-03-03 2025-04-09 Agilent Technologies, Inc. Verfahren und systeme zur funktionellen reifung von kardiomyozyten aus ipsc und esc
JP7336769B2 (ja) 2017-04-19 2023-09-01 シーダーズ―シナイ メディカル センター 骨格筋ジストロフィーを治療する方法及び組成物
WO2019126068A1 (en) 2017-12-20 2019-06-27 Cedars-Sinai Medical Center Engineered extracellular vesicles for enhanced tissue delivery
EP3749344A4 (de) 2018-02-05 2022-01-26 Cedars-Sinai Medical Center Verfahren zur therapeutischen verwendung von exosomen und y-rnas
USD941488S1 (en) 2020-02-07 2022-01-18 Agilent Technologies, Inc. Instrument for analyzing biological cells
US20210301245A1 (en) 2020-03-29 2021-09-30 Agilent Technologies, Inc. Systems and methods for electronically and optically monitoring biological samples

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5486359A (en) * 1990-11-16 1996-01-23 Osiris Therapeutics, Inc. Human mesenchymal stem cells
US6387369B1 (en) 1997-07-14 2002-05-14 Osiris Therapeutics, Inc. Cardiac muscle regeneration using mesenchymal stem cells
US6248587B1 (en) * 1997-11-26 2001-06-19 University Of Southern Cailfornia Method for promoting mesenchymal stem and lineage-specific cell proliferation
DE69937888T2 (de) 1998-07-31 2009-01-02 Genzyme Corp., Cambridge Verfahren zur Herstellung mesenchymaler Stammzellen
US6184035B1 (en) * 1998-11-18 2001-02-06 California Institute Of Technology Methods for isolation and activation of, and control of differentiation from, skeletal muscle stem or progenitor cells
WO2001000031A1 (en) 1999-06-25 2001-01-04 Baylor College Of Medicine Stem cells derived from skeletal muscle
WO2001011011A2 (en) 1999-08-05 2001-02-15 Mcl Llc Multipotent adult stem cells and methods for isolation
HK1052645B (en) * 2000-04-14 2008-03-20 Universtiy Of Pittsburgh Soft tissue and bone augmentation and bulking utilizing muscle-derived progenitor cells, compositions and treatments thereof

Also Published As

Publication number Publication date
US20030082153A1 (en) 2003-05-01
US7220582B2 (en) 2007-05-22
AU2002337949B1 (en) 2003-05-06
US20050058633A1 (en) 2005-03-17
WO2003035838A3 (en) 2003-07-17
JP4377690B2 (ja) 2009-12-02
US20070212423A1 (en) 2007-09-13
WO2003035838A2 (en) 2003-05-01
CA2464088A1 (en) 2003-05-01
EP1444329A4 (de) 2004-11-24
DE60216959D1 (de) 2007-02-01
EP1444329B1 (de) 2006-12-20
EP1444329A2 (de) 2004-08-11
JP2005506845A (ja) 2005-03-10

Similar Documents

Publication Publication Date Title
ATE348878T1 (de) Sich in schlagende kardiomyozyten verwandelnde stammzellen
DK1650307T3 (da) Fremgangsmåde til fremstilling af rekombinante proteiner ved anvendelse af apoptoseinhibitorer
NO20024200D0 (no) Serumfri dyrking av primate embryonale stamceller
DK1082410T3 (da) Humane CD45 - og/eller fibroblast mesenchymale stamceller
HUP0301002A2 (hu) Kettős specifitású ellenanyagok, eljárások előállításukra és alkalmazásaik
NO20013770D0 (no) Metoder og blandinger for å öke antall hvite blodceller
EP1435977A4 (de) Herztransplantation von stammzellen zur behandlung von herzinsuffizienz
BR0214029A (pt) Métodos e composições para o uso de células estromais para suportar células tronco embriÈnicas e adultas
ATE426023T1 (de) ßHEDGEHOG-LIKEß PROTEINE VON WIRBELTIEREN, DIE EMBRYONALE STRUKTUREN INDUZIEREN
DE60144145D1 (de) Subtilisin-variante
EA200501772A1 (ru) Способы измерения экспрессии генов из фиксированного и залитого в парафин образца ткани
DE69433168D1 (de) In vitro vermehrung von stammzellen
ATE324877T1 (de) Behandlung von metastatischer krankheit
DE60117294D1 (de) Formbehälterboden
DE60229848D1 (de) - und organtransplantationen und unterdrückt apoptose
SE0401132D0 (sv) Endotelceller härledda från primata embryonala stamceller
DE60213407D1 (de) Zusammensetzungen zur hemmung der angiogenese
NO20020779D0 (no) Fremgangsmåter, preparater og sett for å fremme helbredelse ved skader på sentralnervesystemet
DE60235836D1 (de) Ahren und verwendung davon
ATE382697T1 (de) Mutierte version der arginin deiminase
AU2001292995A1 (en) Genetically altered mammalian embryonic stem cells, their living progeny, and their therapeutic application for improving cardiac function after myocardial infarction
IS7154A (is) Bv8 kjarnsýrur og fjölpeptíð með mítósu-valdandi verkun
DE60226896D1 (de) Herstellung von f(ab')2 fragmenten in saügetierzelle
EP1285961A4 (de) Verfahren zur schaffung von wirbeltier-spezifischer bauchspeicheldrüse in vitro
NO20041633L (no) Fremgangsmate for fremstilling av heparin fra mastcelle kulturer

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties